Healthcare provider profile · identity verified

Eirene E Koroulakis, MD

Internal Medicine · KENSINGTON, MD · NPI 1396805826

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	663	213
Amlodipine Besylate	Amlodipine Besylate	369	106
Losartan Potassium	Losartan Potassium	361	109
Levothyroxine Sodium	Levothyroxine Sodium	338	100
Lisinopril	Lisinopril	244	67
Atenolol	Atenolol	191	55
Glipizide	Glipizide	157	46
Metformin Hcl	Metformin Hcl	152	44
Rosuvastatin Calcium	Rosuvastatin Calcium	152	46
Pantoprazole Sodium	Pantoprazole Sodium	140	52
Famotidine	Famotidine	136	41
Metoprolol Tartrate	Metoprolol Tartrate	121	39
Albuterol Sulfate Hfa	Albuterol Sulfate	117	63
Hydrochlorothiazide	Hydrochlorothiazide	116	38
Gabapentin	Gabapentin	115	43
Tramadol Hcl	Tramadol Hcl	106	25
Arexvy	Rsvpref3 Antigen/As01e/Pf	104	104
Furosemide	Furosemide	92	39
Pradaxa	Dabigatran Etexilate Mesylate	86	29
Tamsulosin Hcl	Tamsulosin Hcl	86	28
Trazodone Hcl	Trazodone Hcl	86	32
Simvastatin	Simvastatin	80	25
Prednisone	Prednisone	78	53
Meloxicam	Meloxicam	67	36
Allopurinol	Allopurinol	61	17
Jardiance	Empagliflozin	61	20
Clopidogrel	Clopidogrel Bisulfate	60	18
Alendronate Sodium	Alendronate Sodium	57	20
Clonazepam	Clonazepam	56	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	54	46
Zolpidem Tartrate	Zolpidem Tartrate	54	suppressed
Pravastatin Sodium	Pravastatin Sodium	53	18
Chlorthalidone	Chlorthalidone	52	18
Sertraline Hcl	Sertraline Hcl	49	17
Duloxetine Hcl	Duloxetine Hcl	48	15
Potassium Chloride	Potassium Chloride	48	16
Finasteride	Finasteride	46	12
Alvesco	Ciclesonide	44	21
Doxycycline Monohydrate	Doxycycline Monohydrate	43	42
Humulin N	Insulin Nph Human Isophane	43	13
Metformin Hcl Er	Metformin Hcl	43	16
Wixela Inhub	Fluticasone Propion/Salmeterol	43	14
Montelukast Sodium	Montelukast Sodium	42	14
Escitalopram Oxalate	Escitalopram Oxalate	41	14
Spironolactone	Spironolactone	41	16
Acyclovir	Acyclovir	38	18
Citalopram Hbr	Citalopram Hydrobromide	38	11
Hydralazine Hcl	Hydralazine Hcl	35	11
Bupropion Xl	Bupropion Hcl	33	13
Buprenorphine	Buprenorphine	31	suppressed
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	31	12
Pregabalin	Pregabalin	31	suppressed
Azithromycin	Azithromycin	30	17
Eliquis	Apixaban	29	suppressed
Fluticasone Propionate	Fluticasone Propionate	29	11
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	29	suppressed
Methocarbamol	Methocarbamol	29	14
Triamcinolone Acetonide	Triamcinolone Acetonide	29	23
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	28	28
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	28	15
Mirtazapine	Mirtazapine	28	15
Alprazolam	Alprazolam	27	14
Carvedilol	Carvedilol	27	suppressed
Lorazepam	Lorazepam	27	15
Metoprolol Succinate	Metoprolol Succinate	26	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	25	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	25	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	24	suppressed
Spiriva Respimat	Tiotropium Bromide	24	suppressed
Amoxicillin	Amoxicillin	23	14
Azelastine Hcl	Azelastine Hcl	23	13
Ozempic	Semaglutide	23	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	22	suppressed
Solifenacin Succinate	Solifenacin Succinate	22	suppressed
Midodrine Hcl	Midodrine Hcl	21	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	21	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	20	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	20	18
Digoxin	Digoxin	19	suppressed
Hydrocortisone	Hydrocortisone	19	suppressed
Ibuprofen	Ibuprofen	19	14
Propranolol Hcl Er	Propranolol Hcl	19	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	19	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	18	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	18	suppressed
Liraglutide	Liraglutide	18	suppressed
Nifedipine Er	Nifedipine	18	suppressed
Enalapril Maleate	Enalapril Maleate	17	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	17	suppressed
Levetiracetam	Levetiracetam	17	suppressed
Naproxen	Naproxen	17	suppressed
Nystatin	Nystatin	16	12
Ondansetron Odt	Ondansetron	16	14
Oxycodone Hcl	Oxycodone Hcl	16	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	16	13
Celecoxib	Celecoxib	15	suppressed
Cephalexin	Cephalexin	15	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	15	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	15	suppressed
Ketoconazole	Ketoconazole	15	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	14	suppressed
Donepezil Hcl	Donepezil Hcl	14	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	14	suppressed
Colchicine	Colchicine	13	suppressed
Fluocinonide	Fluocinonide	13	suppressed
Insulin Syringe	Syring-Needl,disp,insul,0.3 Ml	13	suppressed
Memantine Hcl	Memantine Hcl	13	suppressed
Mupirocin	Mupirocin	13	suppressed
Armour Thyroid	Thyroid,pork	12	suppressed
Cefdinir	Cefdinir	12	12
Clindamycin Phosphate	Clindamycin Phosphate	12	suppressed
Divalproex Sodium	Divalproex Sodium	12	suppressed
Victoza 2-Pak	Liraglutide	12	suppressed
Fluconazole	Fluconazole	11	suppressed
Halobetasol Propionate	Halobetasol Propionate	11	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed
Methadone Hcl	Methadone Hcl	11	suppressed
Methylphenidate Hcl Er (Cd)	Methylphenidate Hcl	11	suppressed
Omeprazole	Omeprazole	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error